Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Five Positive Opinions From EU's CHMP Brightens Up The New Year

This article was originally published in The Pink Sheet Daily

Executive Summary

New molecular entities from Valeant/GSK, Eisai, Sanofi and Novartis make the grade for the EU's scientific panel at its January meeting.

You may also be interested in...



Novartis' Gilenya Shines Amid Bleak Day for MS Drugs In Europe

European regulators rebuff Fampyra and Movectro, but approve Gilenya.

EU Advisory Panel Clears Sanofi’s Jevtana But Wants to Review Multaq’s Liver Risks

Sanofi-Aventis' cabazitaxel receives a positive opinion from the EU's scientific advisory committee, but the benefit/risk balance of the French company's anti-arrhythmic, Multaq, needs to be reviewed.

Eisai Rides High On Expanded Oncology Capabilities, Enters Neglected Disease Foray

TOKYO - Two days after gaining U.S. FDA approval for its first in-house produced oncology product, Eisai continued its week of "firsts" with the announcement that it is the first Japanese pharmaceutical company to reach a supply agreement with the World Health Organization to combat a neglected tropical disease

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel